Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer

BackgroundTo construct a prediction model consisting of metabolites and proteins in peripheral blood plasma to predict whether patients with unresectable stage III and IV non-small cell lung cancer can benefit from immunotherapy before it is administered.MethodsPeripheral blood plasma was collected...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rui Wu, Kunchen Wei, Xingshuai Huang, Yinge Zhou, Xiao Feng, Xin Dong, Hao Tang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	non-small cell lung cancer immune checkpoint inhibitors metabolomics proteomics prediction models
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1479550/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
by: Lu Zheng, et al.
Published: (2025-01-01)

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy
by: Nao Kobayashi, et al.
Published: (2025-01-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
by: Liang Zheng, et al.
Published: (2024-09-01)

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials
by: Andrea Messori, et al.
Published: (2025-01-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review
by: Rencui Quan, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context
by: Jiacheng Yao, et al.
Published: (2025-03-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Advances in bioinformatics and multi-omics integration: transforming viral infectious disease research in veterinary medicine
by: Alyaa Elrashedy, et al.
Published: (2025-01-01)

Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan
by: Qingqing Hu, et al.
Published: (2025-01-01)

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer
by: Guomin Gu, et al.
Published: (2024-12-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
by: Tadahiro Kuribayashi, et al.
Published: (2025-01-01)

Multi-omics study on the effect of moderate-intensity exercise on protein lactylation in mouse muscle tissue
by: Jiahui Chang, et al.
Published: (2025-01-01)

Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer
by: Jenny Ling-Yu Chen, et al.
Published: (2024-11-01)

Unveiling the mechanism of micro-and-nano plastic phytotoxicity on terrestrial plants: A comprehensive review of omics approaches
by: Asad Jamil, et al.
Published: (2025-01-01)

Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01)

The effect of the relative dose intensity of chemoradiotherapy on the effectiveness of therapy of locally advanced unresectable non-small cell lung cancer
by: A. E. Glukhareva, et al.
Published: (2024-03-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

Editorial: Next generation of omics analysis to study lipid-rich tissues
by: Isabella Piga, et al.
Published: (2025-02-01)

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01)

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-01-01)

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer
by: Yuichi Ozawa, et al.
Published: (2024-11-01)

Comprehensive multi-omics, behavioral and morphological analysis of the hazards of nano-plastics in mice with internal carotid artery occlusion
by: Lu Wang, et al.
Published: (2025-01-01)

Integrated analysis of dermatomyositis reveals heterogeneous immune infiltration and interstitial lung disease-associated endotype
by: Xinzhi Xu, et al.
Published: (2025-02-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

Multi-omics uncovers immune-modulatory molecules in plasma contributing to resistance exercise-ameliorated locomotor disability after incomplete spinal cord injury
by: Ren Zhou, et al.
Published: (2025-02-01)

Long term survival of advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: a case report
by: Xiaoli Wang, et al.
Published: (2025-02-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

MicroRNA-150-3p enhances the antitumour effects of CGP57380 and is associated with a favourable prognosis in non-small cell lung cancer
by: Hongmei Zheng, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)